This content is machine translated SGLT-2 inhibitors Dapagliflozin now also available for non-diabetics for the treatment of heart failure (HFrEF) Based on the results of the DAPA-HF study, Swissmedic has approved dapagliflozin for the treatment of heart failure with reduced ejection fraction (HFrEF), whether or not patients have type 2…
View Post 3 min This content is machine translated Diabetes Cases Type 2 diabetes mellitus with incipient kidney damage A 58-year-old preadipose patient with type 2 diabetes mellitus and other comorbidities is diagnosed with incipient renal impairment during a workup. This makes it necessary to adjust the diabetes therapy.
View Post 4 min This content is machine translated Reflux Cases Management of mild and moderate gastric distress in family practice. Marcel Halama, MD, interviewed on the key aspects of managing reflux and its limitations.
View Post 3 min This content is machine translated Rheumatoid arthritis Using “windows of opportunity” for disease-modifying therapy. Diagnosis at an early stage of the disease is a prerequisite to take advantage of the time window for optimally effective disease-modifying therapy (DMARD). This not only enables a reduction…
View Post 2 min This content is machine translated SGLT2 inhibitor convinces Dapagliflozin may score well in nephro- and cardioprotection Patients with diabetic nephropathy can now be effectively treated with SGLT2 inhibitors. They are also said to have cardioprotective effects. Dapagliflozin is now the first and only antidiabetic agent approved…
View Post 4 min This content is machine translated GLP-1 receptor agonists Jack of all trades in the fight against type 2 diabetes GLP-1 receptor agonists (RA) have been used in the treatment of diabetic patients since 2005. For patients, their introduction was a milestone, as GLP-1 RAs have the great advantage of…
View Post 5 min This content is machine translated Type 2 diabetes mellitus Heart and kidney protected in different patient groups Approximately 40% of patients with type 2 diabetes mellitus (T2DM) develop diabetic kidney disease, which contributes to increased cardiovascular and mortality risk [1, 2]. This makes it all the more…
View Post 3 min This content is machine translated Type 1 diabetes Despite known cardiac risk, many patients are undertreated Cardiac problems such as coronary artery disease and heart failure are among the most common and dangerous complications of type 1 diabetes. The mortality risk is significantly increased. Although this…
View Post 4 min This content is machine translated Diabetes Cases Type 2 diabetes mellitus and marked obesity A 48-year-old, severely obese patient is diagnosed with full-blown metabolic syndrome during an operative evaluation of osteoarthritis of the upper ankle. His arterial hypertension, dyslipidemia, hyperuricemia, grade III obesity, and…
View Post 7 min This content is machine translated Diabetes Management Nephro- and cardioprotection as an interdisciplinary challenge Early detection and treatment of renal dysfunction and cardiovascular risk factors in type 2 diabetes mellitus is essential. Experts see a need for action in this area, especially with regard…
View Post 6 min This content is machine translated RA therapy Let’s talk about JAKs The treatment of rheumatoid arthritis (RA) has made great progress over the past 20 years. This relates both to the range of drugs available and to developments in terms of…
